Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet Haematology; February 2024, Vol. 11 Issue: 2 pe101-e113, 13p
- Subject
- Language
- ISSN
- 23523026